Degludec Insulin Injection Receives Marketing Approval
July 31, 2026
Source: drugdu
37
On July 30, Dongyangguang Pharmaceutical (06887) announced that its independently developed insulin degludec injection has received marketing approval from the National Medical Products Administration (NMPA). The drug is available in both cartridge and pre-filled injection pen versions.
Insulin degludec injection is a fourth-generation long-acting basal insulin analog with a half-life of approximately 25 hours and a duration of action exceeding 42 hours, allowing for once-daily dosing to meet the entire day's basal insulin requirements. Furthermore, this drug is superior to insulin glargine in terms of glucose-lowering curve stability and the incidence of hypoglycemia.
With the launch of insulin degludec injection, the company now offers six insulin products in the Chinese market, covering three major clinical application scenarios: basal, prandial, and premixed insulin. The company is also pursuing international registration for other insulin products to expand its international market share.
https://finance.eastmoney.com/a/202607303826929962.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- While Da Vinci Remains in “Remote Control” Mode, Cornerstone Robotics Has Evolved to “Autonomous Operation”—A Technological Leap for Domestic Surgical Robots July 31, 2026
- Carbamazepine Extended-Release Tablets (II) Receive Drug Registration Certificate July 31, 2026
- Levocarnitine Oral Solution Receives Drug Registration Certificate July 31, 2026
- Application for drug registration and marketing authorization of dapagliflozin tablets accepted July 31, 2026
- China Biopharmaceutical and Indonesia’s Tempo Scan establish a joint venture with China Biopharmaceutical holding a 51% stake to expand the Southeast Asian pharmaceutical market July 31, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
